The latest price target for Cellebrite DI (NASDAQ:CLBT) was reported by Craig-Hallum on November 7, 2024. The analyst firm set a price target for $24.00 expecting CLBT to rise to within 12 months (a possible 20.45% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Cellebrite DI (NASDAQ:CLBT) was provided by Craig-Hallum, and Cellebrite DI maintained their buy rating.

The last upgrade for Cellebrite DI Ltd happened on March 13, 2024 when William Blair raised their price target to N/A. William Blair previously had a market perform for Cellebrite DI Ltd.

The last downgrade for Cellebrite DI Ltd happened on August 12, 2022 when B of A Securities changed their price target from $6.5 to $6 for Cellebrite DI Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellebrite DI, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellebrite DI was filed on November 7, 2024 so you should expect the next rating to be made available sometime around November 7, 2025.

While ratings are subjective and will change, the latest Cellebrite DI (CLBT) rating was a maintained with a price target of $23.00 to $24.00. The current price Cellebrite DI (CLBT) is trading at is $19.92, which is out of the analyst’s predicted range.